Why Insulin Resistance and Chronic Inflammation May Begin Years Before Disease Is Diagnosed
Imagine going to your doctor for a routine physical.
Your blood pressure looks fine.
Your cholesterol numbers appear normal.
Your triglycerides fall within the standard range.
Your blood sugar appears normal.
Your doctor tells you everything looks good.
But what if something important was already happening beneath the surface?
What if the biological processes that lead to many chronic diseases – conditions such as type 2 diabetes, cardiovascular disease, metabolic syndrome, and even cognitive decline – had already begun years earlier?
Research over the past several decades suggests that this is often exactly what happens.
Long before many chronic diseases are diagnosed, the body may already be experiencing rising insulin levels, insulin resistance, and chronic low-grade inflammation.
These changes can quietly develop over years while traditional laboratory markers remain normal.
Understanding these early metabolic signals may help explain why so many people are surprised when they are suddenly diagnosed with conditions that seem to appear overnight.
In reality, those diseases often begin developing long before symptoms appear.
The Test Most Doctors Never Ran
Despite decades of metabolic research, one laboratory marker is still not routinely tested in many clinical settings: fasting insulin.
Most routine metabolic panels measure:
-
- fasting glucose
- hemoglobin A1c
- cholesterol
- triglycerides
- blood pressure
These markers are valuable and widely used.
However, they often detect disease after metabolic dysfunction has already been developing for years.
Fasting insulin can often reveal metabolic stress much earlier, yet it is rarely included in routine testing.
This is not because physicians do not care. Rather, it reflects how medical training and diagnostic guidelines evolved historically.
A Conversation I Never Forgot
In 2011, I remember sitting with two physicians discussing metabolic health.
I asked what seemed like a straightforward question.
“Why isn’t it standard practice for physicians to order both fasting glucose and fasting insulin?”
One of the physicians replied,
“You stick to nutrition and leave that to us, doctors. If you have the fasting glucose, you don’t need to know the fasting insulin.”
That moment stayed with me.
Not because I was offended, but because it revealed something important about how medicine often works.
Most physicians practice according to the diagnostic frameworks they were trained to follow.
Medical education is rigorous and structured, and doctors rely heavily on established guidelines.
But when new scientific insights emerge, it can take many years for them to become routine clinical practice.
What the Research Has Shown
Multiple long-term studies have shown that hyperinsulinemia and insulin resistance often develop years before type 2 diabetes is diagnosed.
The San Antonio Heart Study demonstrated that elevated fasting insulin levels predicted the development of type 2 diabetes even when glucose levels remained normal (2).
Research associated with Harvard Medical School and the Joslin Diabetes Center has also documented that abnormalities in insulin secretion and insulin sensitivity may occur many years before diabetes develops (3,4).
These findings suggest that insulin resistance may represent one of the earliest detectable stages of metabolic dysfunction.
Evidence From Cardiovascular Research
Insulin resistance is also strongly associated with cardiovascular disease.
The Quebec Cardiovascular Study found that hyperinsulinemia was an independent risk factor for coronary heart disease (10).
Similarly, the Framingham Offspring Study demonstrated that insulin resistance significantly increased the risk of both cardiovascular disease and type 2 diabetes (3).
Together, these findings suggest that metabolic dysfunction often begins years before cardiovascular disease becomes clinically apparent.
Insulin Resistance and Cholesterol
Insulin resistance also alters lipid metabolism.
When insulin resistance develops, the liver increases production of very-low-density lipoproteins (VLDL).
This metabolic shift contributes to the formation of small dense LDL particles, which are considered more atherogenic because they:
-
- penetrate arterial walls more easily
- remain in circulation longer
- are more susceptible to oxidative damage
This lipid pattern is often referred to as atherogenic dyslipidemia, and it is strongly associated with insulin resistance (11).
Importantly, these changes can occur before traditional cholesterol markers appear abnormal.
The Inflammation Connection
Another major factor in metabolic disease is chronic low-grade inflammation.
Inflammation is a natural biological response that helps the body repair tissue and fight infection.
However, when inflammatory signaling remains elevated over long periods, it can disrupt metabolic processes.
Inflammatory molecules can interfere with insulin signaling, while elevated insulin levels may further stimulate inflammatory pathways.
This creates a biological cycle in which inflammation and insulin resistance reinforce one another.
The Cellular Origin of Inflammation
To better understand inflammation, we must examine the cell membrane.
Cell membranes are composed largely of fatty acids.
Two fatty acids play particularly important roles in inflammatory signaling:
Arachidonic Acid (AA) – an omega-6 fatty acid
Eicosapentaenoic Acid (EPA) – an omega-3 fatty acid
These fatty acids compete to produce signaling molecules called eicosanoids, which regulate inflammatory responses throughout the body.
When AA dominates in cell membranes, the body tends to produce more pro-inflammatory signaling molecules.
When EPA levels increase, inflammatory signaling tends to become more balanced (7,8).
Researchers often evaluate this balance using the AA/EPA ratio.
Measuring Inflammation at the Cellular Level
One way to evaluate fatty acid balance is through red blood cell membrane testing.
Because red blood cells circulate for approximately 120 days, their membranes provide insight into long-term fatty acid patterns.
Today, this information can be obtained through dried blood spot testing, such as the BalanceTest, which evaluates omega-6 and omega-3 fatty acids and calculates markers such as the AA/EPA ratio.
These measurements provide insight into the body’s inflammatory signaling environment.
How the Modern Diet Shifted Fatty Acid Balance
Anthropological evidence suggests that throughout much of human evolution, the omega-6-to-omega-3 ratio in the human diet was approximately 1:1.
However, during the past century, the widespread use of industrial seed oils dramatically increased omega-6 intake.
Examples include:
-
- soybean oil
- corn oil
- sunflower oil
- safflower oil
- cottonseed oil
At the same time, intake of omega-3 fatty acids declined.
Today many researchers estimate that the modern omega-6 to omega-3 ratio ranges from 10:1 to 20:1 (7,12).
This imbalance may contribute to increased inflammatory signaling.
Insulin Resistance, Inflammation, and Brain Health
Researchers are also investigating how metabolic dysfunction may influence cognitive decline and dementia.
Large epidemiological studies have shown that individuals with metabolic disorders such as type 2 diabetes and insulin resistance have a significantly higher risk of developing dementia, including Alzheimer’s disease (13).
One proposed mechanism involves insulin-degrading enzyme (IDE).
IDE helps break down both insulin and amyloid-beta, the protein associated with plaque formation in Alzheimer’s disease.
When insulin levels remain chronically elevated, IDE may prioritize breaking down insulin, potentially leaving less capacity to clear amyloid-beta from the brain (14).
Because of this growing evidence linking metabolic dysfunction to neurodegenerative disease, some researchers have referred to Alzheimer’s disease as “Type 3 diabetes.” (16)
Women, Brain Health, and Metabolic Risk
Women account for nearly two-thirds of Alzheimer’s cases in the United States.
While several factors may contribute to this difference, including longevity and hormonal changes later in life, the statistics highlight an opportunity to raise awareness of metabolic health early, particularly among women.
Women are also more likely than men to take action when it comes to preventive health care.
This reinforces the importance of understanding markers such as fasting insulin and evaluating inflammation through tools such as the BalanceTest, which measures the omega-6 to omega-3 balance and the AA/EPA ratio.
The Silent Phase of Chronic Disease
Many chronic diseases develop slowly.
During the early “silent phase” of metabolic dysfunction, several biological changes may occur:
-
- rising fasting insulin
- insulin resistance
- chronic inflammation
- lipid abnormalities
- vascular dysfunction
Routine laboratory tests may still appear normal.
To the patient, the disease appears suddenly.
Biologically, it often develops over many years.
The Bottom Line
Most chronic diseases do not begin the day they are diagnosed.
They often begin years earlier with changes in insulin signaling, inflammation, fatty acid balance, and metabolic function.
Understanding these early processes allows both patients and healthcare professionals to look more deeply into the biological signals that influence long-term health.
If You Want to Learn More
If you are a physician, I would welcome the opportunity to connect with you. I have a special package designed specifically for medical professionals interested in understanding metabolic health, inflammation, and insulin resistance.
If you want to learn how to get your fasting insulin tested without going through your physician, I can help point you in the right direction.
If you would like to learn more about at-home testing that evaluates inflammation at the cellular level, including tests that measure omega-6 to omega-3 balance, contact the person who shared this article with you.
You may also contact me directly: robert@dietfreelife.com
References
-
- Reaven, G. M. (1988). Role of insulin resistance in human disease. Diabetes.
- Haffner, S. M., et al. (1990). Hyperinsulinemia and risk of type 2 diabetes. The New England Journal of Medicine.
- Meigs, J. B., et al. (2007). Insulin resistance and cardiovascular risk. Diabetes Care.
- Shanik, M. H., et al. (2008). Insulin resistance and hyperinsulinemia. Diabetes Care.
- Samuel, V. T., & Shulman, G. I. (2012). Mechanisms for insulin resistance. Cell.
- Libby, P. (2002). Inflammation in atherosclerosis. Nature.
- Simopoulos, A. P. (2002). Omega-6/omega-3 fatty acid ratio and disease. Biomedicine & Pharmacotherapy.
- Calder, P. C. (2015). Marine omega-3 fatty acids and inflammation. Biochimica et Biophysica Acta.
- Harris, W. S., & von Schacky, C. (2004). The omega-3 index. Preventive Medicine.
- Després, J. P., et al. (1996). Hyperinsulinemia as an independent risk factor for ischemic heart disease. The New England Journal of Medicine.
- Krauss, R. M. (2004). Lipids and lipoproteins in type 2 diabetes. Diabetes Care.
- Simopoulos, A. P. (2016). Omega-6/omega-3 imbalance and disease risk. Nutrients.
- Biessels, G. J., & Despa, F. (2018). Cognitive decline and dementia in diabetes. The Lancet Neurology.
- Farris, W., et al. (2003). Insulin-degrading enzyme and amyloid beta. Proceedings of the National Academy of Sciences.
- Morris, M. C., et al. (2003). Fish intake and Alzheimer’s disease risk. Archives of Neurology.
- de la Monte, S. M., & Wands, J. R. (2008). Alzheimer’s disease is type 3 diabetes. Journal of Diabetes Science and Technology.
__________
Robert Ferguson is a California- and Florida-based single father of two daughters, clinical nutritionist, Omega Balancing Coach™, researcher, best-selling author, speaker, podcast and television host, health advisor, NAACP Image Award Nominee, creator of the Diet Free Life methodology, and Chief Nutrition Officer for iCoura Health. He also serves on the Presidential Task Force on Obesity for the National Medical Association and the Health and Product Advisory Board for Zinzino, Inc.
🗓️ Schedule a FREE consultation with Robert Ferguson about becoming a client: SCHEDULE FREE CONSULTATION
👉🏽 To order the BalanceOil+ with the BalanceTEST, > CLICK HERE
👉🏽 Watch a free online presentation on the BalanceOil+ and the BalanceTEST: WATCH NOW.
0 Comments